Provided by Tiger Fintech (Singapore) Pte. Ltd.

Olema Pharmaceuticals, Inc.

4.98
-0.3900-7.26%
Post-market: 4.90-0.0800-1.61%17:32 EDT
Volume:469.89K
Turnover:2.40M
Market Cap:340.74M
PE:-2.56
High:5.36
Open:5.31
Low:4.98
Close:5.37
Loading ...

Olema Pharmaceuticals Says OP-3136 Molecule Shows Anti-Tumor Activity in Preclinical Models

MT Newswires Live
·
26 Apr

Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025

GlobeNewswire
·
26 Apr

Promising Outlook for Olema Pharmaceuticals: Buy Rating Affirmed Amid Strategic Positioning in ER+ Breast Cancer Treatment

TIPRANKS
·
14 Apr

Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
03 Apr

Olema Pharmaceuticals Is Maintained at Overweight by JP Morgan

Dow Jones
·
28 Mar

Olema Oncology to Present Preclinical Data for OP-3136, a Potent KAT6 Inhibitor, Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at the 2025 AACR Annual Meeting

GlobeNewswire
·
26 Mar

North American Morning Briefing: Stock Futures Fall as Focus Shifts From Fed to Tariffs

Dow Jones
·
21 Mar

Analysts Are Bullish on Top Healthcare Stocks: Integer Holdings (ITGR), Olema Pharmaceuticals (OLMA)

TIPRANKS
·
20 Mar

Olema Pharmaceuticals Price Target Cut to $25.00/Share From $30.00 by Oppenheimer

Dow Jones
·
20 Mar

Olema Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
19 Mar

Promising Clinical Data and Market Opportunities Drive Buy Rating for Olema Pharmaceuticals

TIPRANKS
·
19 Mar

Oppenheimer Remains a Buy on Olema Pharmaceuticals (OLMA)

TIPRANKS
·
19 Mar

Olema Pharmaceuticals Q4 Net Loss Widens

MT Newswires Live
·
19 Mar

Olema Pharmaceuticals Q4 2024 GAAP EPS $(0.51) Beats $(0.63) Estimate

Benzinga
·
19 Mar

BRIEF-Olema Oncology Q4 Net Income USD -33.567 Million

Reuters
·
19 Mar

Press Release: Olema Oncology Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

Dow Jones
·
19 Mar

Olema Pharmaceuticals Inc expected to post a loss of 64 cents a share - Earnings Preview

Reuters
·
17 Mar

Olema Pharmaceuticals Price Target Maintained With a $30.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Mar

Promising Efficacy of Olema Pharmaceuticals’ Palazestrant Supports Buy Rating

TIPRANKS
·
11 Mar

Olema Pharmaceuticals: Promising Clinical Results and Strong Financial Health Support Buy Rating

TIPRANKS
·
07 Mar